<DOC>
	<DOCNO>NCT01954615</DOCNO>
	<brief_summary>Study Part I single-ascending dose study . Healthy male subject include study randomize 6 dose group , Groups A-F ( 8 subject per group ) . Of 8 subject per group , 6 subject receive investigational drug 2 subject receive match placebo . Study Part II 3-period , crossover , single dose study . Nine healthy male subject enrol one group ( Group G ) . Each subject receive 2 different formulation prodrug one formulation active drug randomize sequence .</brief_summary>
	<brief_title>Single-ascending Oral Dose Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ACT-281959 / ACT-246475 Healthy Male Subjects</brief_title>
	<detailed_description>Study Part I prospective , single-center , double-blind , randomize , placebo-controlled , single-ascending dose , Phase 1 study . Approximately 48 healthy male subject include study randomize 6 dose group , Groups A-F ( 8 subject per group ) . Of 8 subject per group , 6 subject receive investigational drug 2 subject receive match placebo . Study Part II prospective , single-center , open-label , randomize , 3-period , crossover , single dose , Phase 1 study . Nine healthy male subject enrol one group , Group G. Each subject receive 2 different formulation prodrug one formulation active drug randomize sequence .</detailed_description>
	<criteria>Signed informed consent local language prior studymandated procedure . Healthy male subject age 18 45 year ( inclusive ) screening . No clinically significant finding physical examination screening . Body mass index 18.0 28.0 kg/m^2 ( inclusive ) screening . Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , pulse rate 4590 beat per minute ( inclusive ) , measure dominant arm , 5 minute supine position screening . 12lead electrocardiogram without clinically relevant abnormality , measure 5 minute supine position screening . Hematology , coagulation , clinical chemistry , urinalysis test result deviate clinically relevant extent normal range screening . Negative result urine drug screen screen . Baseline value maximal ( peak ) platelet aggregation ≥ 50 % light transmission aggregometry upon 20 μM adenosine diphosphate ( ADP ) activation screen . Baseline value closure time test platelet function analyser 100 , cartridge Collagen/Epinephrine Collagen/ADP upper limit normal range . Ability communicate well investigator local language , understand comply requirement study . Known allergic reaction hypersensitivity excipient drug formulation ( ) . History clinical evidence disease and/or existence surgical medical condition would interfere absorption , distribution , metabolism , excretion study drug ( appendectomy herniotomy allow , cholecystectomy allow ) . Previous history fainting , collapse , orthostatic hypotension , vasovagal reaction . Family personal history bleeding ( e.g. , stroke , major trauma , surgical intervention ) , bleed disorder ( e.g. , thrombocytopenia , clot disturbance , intracranial vascular disease , peptic ulcer ) , reasonable suspicion vascular malformation . Platelet count ˂ 120x10^9/L screening . Veins unsuitable intravenous puncture either arm ( e.g. , vein difficult locate , access , puncture , vein tendency rupture puncture ) . Treatment another investigational drug within 3 month prior screen participation four investigational drug study within 1 year prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . Excessive caffeine consumption , define ≥ 800 mg per day screening . Smoking within 3 month prior screen inability refrain smoke course study . Previous treatment prescribe overthecounter medication ( include herbal medicine St. Johnʼs Wort ) especially acetyl salicylic acid , nonsteroidal antiinflammatory , anticoagulant medication ( e.g. , heparin , warfarin ) , within 2 week prior ( first ) administration study drug . Loss 250 mL blood within 3 month prior screen . Positive result hepatitis serology , except vaccinated subject subject past resolve hepatitis , screen . Positive result human immunodeficiency virus serology screen . Any circumstance condition , , opinion investigator , would affect full participation study compliance protocol . Legal incapacity limit legal capacity screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>ACT-281959</keyword>
	<keyword>ACT-246475</keyword>
</DOC>